{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:28:26Z","timestamp":1793662106254,"version":"4.5.1"},"reference-count":47,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T00:00:00Z","timestamp":1676332800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Fundation of China","doi-asserted-by":"crossref","award":["82072328"],"award-info":[{"award-number":["82072328"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Fundation of China","doi-asserted-by":"crossref","award":["81930112"],"award-info":[{"award-number":["81930112"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Beijing Hospitals Authority Youth Programme","award":["QML20211602"],"award-info":[{"award-number":["QML20211602"]}]},{"name":"Beijing Public Health Experts Project","award":["2022-2-010"],"award-info":[{"award-number":["2022-2-010"]}]},{"name":"Capital's Funds for Health Improvement and Research","award":["2020-2-2161"],"award-info":[{"award-number":["2020-2-2161"]}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2023,2,14]]},"abstract":"<jats:p>The global rise in antibiotic-resistant nontuberculous mycobacteria has prompted the urgent need for new antimicrobials, especially oral antibiotics. Currently, adverse effects have limited the use of tetracycline-class antibiotics, particularly tigecycline (TGC), in the treatment of rapidly growing mycobacteria (RGM).<\/jats:p>","DOI":"10.1128\/spectrum.03238-22","type":"journal-article","created":{"date-parts":[[2022,12,8]],"date-time":"2022-12-08T14:01:46Z","timestamp":1670508106000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":22,"title":["<i>In Vitro<\/i>\n            Antimicrobial Activities of Tigecycline, Eravacycline, Omadacycline, and Sarecycline against Rapidly Growing Mycobacteria"],"prefix":"10.1128","volume":"11","author":[{"given":"Tingting","family":"Zhang","sequence":"first","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Du","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Dong","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fen","family":"Wang","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Zhao","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junnan","family":"Jia","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congli","family":"Wang","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengli","family":"Cheng","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Yu","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4295-4262","authenticated-orcid":true,"given":"Hairong","family":"Huang","sequence":"additional","affiliation":[{"name":"National Clinical Laboratory on Tuberculosis, Beijing Key Laboratory for Drug-Resistant Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Institute, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00250-2019"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2406.172095"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2403.171301"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2311.170959"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2016.08.020"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2017.11.001"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00535-2020"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01991-2018"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-571ST"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2021.07.035"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201111-2005OC"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/506598"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhin.2007.05.006"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.10.3164-3167.2002"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2017-210927"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku062"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.01977"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2019.10.006"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01067-3"},{"key":"e_1_3_3_21_2","unstructured":"Tetraphase Pharmaceuticals Inc. 2018. Xerava (eravacycline) for injection (package insert). Tetraphase Pharmaceuticals Inc. Watertown MA."},{"key":"e_1_3_3_22_2","unstructured":"Paratek Pharmaceuticals Inc. 2018. Nuzyra (omadacycline) for injection for intravenous use (package insert). Paratek Pharmaceuticals Inc. Boston MA."},{"key":"e_1_3_3_23_2","unstructured":"Allergan USA Inc. 2018. Seysara (sarecycline) for oral use (package insert). Allergan USA Inc. Madison MA."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11030324"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb-2019-0199"},{"key":"e_1_3_3_26_2","first-page":"333","article-title":"Efficacy and safety of sarecycline, a novel, once-daily, narrow spectrum antibiotic for the treatment of moderate to severe facial acne vulgaris: results of a phase 2, dose-ranging study","volume":"17","author":"Leyden JJ","year":"2018","unstructured":"Leyden JJ, Sniukiene V, Berk DR, Kaoukhov A. 2018. Efficacy and safety of sarecycline, a novel, once-daily, narrow spectrum antibiotic for the treatment of moderate to severe facial acne vulgaris: results of a phase 2, dose-ranging study. J Drugs Dermatol 17:333\u2013338.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01206-17"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2022.2085881"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-019-00767-z"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.10.010"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00470-19"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01704-21"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.01928-21"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01174-18"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab238"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac068"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.869237"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab002"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11060722"},{"key":"e_1_3_3_40_2","first-page":"45","article-title":"Sarecycline and the narrow-spectrum tetracycline concept: currently available data and potential clinical relevance in dermatology","volume":"13","author":"Del Rosso JQ","year":"2020","unstructured":"Del Rosso JQ. 2020. Sarecycline and the narrow-spectrum tetracycline concept: currently available data and potential clinical relevance in dermatology. J Clin Aesthet Dermatol 13:45\u201348.","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15275"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-022-00731-y"},{"key":"e_1_3_3_43_2","unstructured":"Woods GL Brown-Elliott BA Conville PS Desmond EP Hall GS Lin G Pfyffer GE Ridderhof JC Siddiqi SH Wallace RJ Jr Warren NG Witebsky FG. 2011. Susceptibility testing of mycobacteria nocardiae and other aerobic actinomycetes [Internet] 2nd ed. Report no. M24-A2 Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv499"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/1469-0691.12405"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn214"},{"key":"e_1_3_3_47_2","unstructured":"Clinical and Laboratory Standards Institute. 2018. Performance Standards for Susceptibility Testing of Mycobacteria Nocardia spp. and Other Aerobic Actinomycetes. CLSI document M62. Clinical and Laboratory Standards Institute Wayne PA."},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02306-20"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.03238-22","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.03238-22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T14:40:45Z","timestamp":1676385645000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.03238-22"}},"subtitle":[],"editor":[{"given":"Gyanu","family":"Lamichhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,2,14]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2,14]]}},"alternative-id":["10.1128\/spectrum.03238-22"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.03238-22","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,14]]},"assertion":[{"value":"2022-08-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-11-11","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e03238-22"}}